Shanghai Lingda Biological Medicine

Lingda Biotech is a Shanghai-based biopharmaceutical company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design bifunctional molecules like PROTACs and molecular glues to address undruggable targets in oncology and immunology. Founded by industry veterans with extensive experience in medicinal chemistry, Lingda aims to overcome drug resistance and improve clinical outcomes for patients with solid tumors and hematological malignancies. The company's research focus includes the degradation of nuclear receptors and transcription factors that have traditionally been difficult to target with small molecule inhibitors. Lingda is currently advancing a pipeline of pre-clinical candidates toward Investigational New Drug (IND) applications. The firm has successfully secured venture capital funding from prominent investors to support its R&D operations in the Zhangjiang Hi-Tech Park.